Drug
Hyperpolarized [13C] Pyruvate
Hyperpolarized [13C] Pyruvate is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed267%
enrolling_by_invitation133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
NCT04019002
enrolling_by_invitationphase_1
A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers
NCT05041166
completedphase_2
Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy
NCT04951921
Clinical Trials (3)
Showing 3 of 3 trials
NCT04019002Phase 1
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
NCT05041166Phase 1
A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers
NCT04951921Phase 2
Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3